Potential for SERMs as Adjunctive Therapy for Schizophrenia
Raloxifene has demonstrated mostly positive results in meta-analyses of men and women with schizophrenia who received the selective estrogen receptor modulator as adjunctive therapy.
Suzanne Bujara
Contributing Writer https://www.psychiatryadvisor.com
Suzanne Bujara is a medical writer with more than 20 years of experience. She writes for continuing medical education and public health programs. She has a BA in linguistics from Douglass College, Rutgers, The State University of New Jersey and an MBA from Rutgers Business School. Before starting her freelance business in 2016, Suzanne wrote for Medscape Education, myCME, praxis.md, and Medical Economics magazine. To learn more about Suzanne, visit
www.suzannebujara.com and www.linkedin.com/in/suzannebujara.
